India's Semaglutide Patent Expiration to Enable Entry of 50 Branded Generics
The expiration of India's semaglutide patent on March 20 is set to significantly impact the global obesity treatment landscape with the entry of numerous generics.
Government, policy, institutions, and political power dynamics.